Patents by Inventor Eva Van Rooij
Eva Van Rooij has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220088052Abstract: The present invention relates to novel treatments for treating cardiac disease involving fibro-fatty replacement, such as arrhythmogenic cardiomyopathy, atrial fibrillation, myocardial infarction and dilated cardiomyopathy. Such cardiac diseases can e.g. be caused by a mutation in a desmosomal protein such as plakophilin-2 (PKP2). The invention provides for agents for use in the prevention or treatment of such cardiac diseases, wherein the agent is at least one of: a) an agent that causes a reduction in expression in at least one TFAP2 subtype; and, b) an agent that causes a reduction in TFAP2-induced transcription. More preferably the agent is at least one of: a) an inhibitor of TFAP2; and, b) an agent that causes an increase in expression of PKP2.Type: ApplicationFiled: January 22, 2020Publication date: March 24, 2022Applicant: Koninklijke Nederlandse Akademie van WetenschappenInventors: Eva van Rooij, Arwa Obada Abdelrahman Reda Kohela
-
Publication number: 20200190511Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: ApplicationFiled: July 11, 2019Publication date: June 18, 2020Inventors: Eric N. Olson, Eva van Rooij
-
Patent number: 10392618Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: GrantFiled: June 30, 2017Date of Patent: August 27, 2019Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Eric N. Olson, Eva van Rooij
-
Patent number: 10337005Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: September 13, 2017Date of Patent: July 2, 2019Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Publication number: 20190127734Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2018Publication date: May 2, 2019Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20180273944Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: September 13, 2017Publication date: September 27, 2018Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Publication number: 20180163204Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: ApplicationFiled: June 30, 2017Publication date: June 14, 2018Inventors: Eric N. OLSON, Eva van ROOIJ
-
Patent number: 9994847Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: June 7, 2016Date of Patent: June 12, 2018Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Patent number: 9803202Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: May 13, 2016Date of Patent: October 31, 2017Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Christina Marie Dalby, Rusty L. Montgomery
-
Patent number: 9752143Abstract: The present invention provides oligonucleotides with chemical motifs that are miR-145 inhibitors. The oligonucleotides can be used for the treatment and prevention of a condition by inhibiting the expression or activity of miR-145 in cells of a subject in need thereof. Methods provided include treating or preventing pulmonary arterial hypertension, neointima formation, restenosis or hypertension in a subject in need thereof by administering to the subject an inhibitor of miR-145 expression or activity. Pharmaceutical compositions and kits comprising miR-145 inhibitors are also disclosed.Type: GrantFiled: March 13, 2014Date of Patent: September 5, 2017Assignee: MIRAGEN THERAPEUTICS, INC.Inventors: Anita G. Seto, Eva van Rooij, Kathryn H. Hutnick, Christina M. Dalby, Thomas G. Hullinger, Rusty Montgomery
-
Patent number: 9719086Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: GrantFiled: January 8, 2015Date of Patent: August 1, 2017Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Eric N. Olson, Eva van Rooij
-
Patent number: 9719088Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: GrantFiled: January 8, 2015Date of Patent: August 1, 2017Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Eric N. Olson, Eva van Rooij
-
Patent number: 9719087Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: GrantFiled: January 8, 2015Date of Patent: August 1, 2017Assignee: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Eric N. Olson, Eva van Rooij
-
Publication number: 20160355815Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: ApplicationFiled: June 7, 2016Publication date: December 8, 2016Inventors: Rusty L. MONTGOMERY, Christina M. DALBY, Eva VAN ROOIJ, Corrie GALLANT-BEHM
-
Publication number: 20160326526Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: ApplicationFiled: May 13, 2016Publication date: November 10, 2016Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9428749Abstract: The disclosure provides a method of regulating fatty acid or glucose metabolism in a cell by contacting the cell with a modulator of miR-208a and/or miR-208b activity or expression. The disclosure also provides a method of treating or preventing a metabolic disorder, such as obesity, diabetes, or metabolic syndrome, in a subject by administering to the subject an inhibitor of miR-208a and/or miR-208b activity or expression. Also provided is a method of enhancing or improving mitochondrial function and/or redox-homeostasis in a subject by administering to the subject an inhibitor of miR-208a and/or miR-208b activity or expression.Type: GrantFiled: October 9, 2012Date of Patent: August 30, 2016Assignees: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MIRAGEN THERAPEUTICS, INC.Inventors: Eva van Rooij, Eric Olson, Chad Grueter, Rusty Montgomery
-
Patent number: 9388408Abstract: The present invention relates to chemical modification motifs for oligonucleotides. The oligonucleotides of the present invention, such as chemically modified antisense oligonucleotides, can have increased in vivo efficacy. The chemically modified oligonucleotides provide advantages in one or more of potency, efficiency of delivery, target specificity, toxicity, and/or stability. The chemically modified oligonucleotides have a specific chemical modification motif or pattern of locked nucleic acids (LNAs). The oligonucleotide (e.g. antisense oligonucleotide) can target RNA, such as miRNA or mRNA. Also provided herein are compositions comprising the chemically modified oligonucleotides and methods of using the chemically modified oligonucleotides as therapeutics for various disorders, including cardiovascular disorders.Type: GrantFiled: June 21, 2013Date of Patent: July 12, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Eva van Rooij, Christina M. Dalby, Rusty L. Montgomery
-
Patent number: 9376681Abstract: The present invention relates to synthetic oligonucleotide mimetics of miRNAs. In particular, the present invention provides double-stranded, chemically-modified oligonucleotide mimetics of miR-29. Pharmaceutical compositions comprising the mimetics and their use in treating or preventing conditions associated with dysregulation of extracellular matrix genes, such as tissue fibrotic conditions, are also described.Type: GrantFiled: September 8, 2015Date of Patent: June 28, 2016Assignee: miRagen Therapeutics, Inc.Inventors: Rusty L. Montgomery, Christina M. Dalby, Eva Van Rooij, Corrie Gallant-Behm
-
Publication number: 20160145608Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: ApplicationFiled: January 8, 2015Publication date: May 26, 2016Inventors: ERIC N. OLSON, EVA VAN ROOIJ
-
Publication number: 20160145609Abstract: The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response to stress, and are up-regulated in heart tissue of mice that are resistant to both stress and fibrosis. Also provided are methods of modulating expression and activity of the miR-29 family of miRNAs as a treatment for fibrotic disease, including cardiac hypertrophy, skeletal muscle fibrosis other fibrosis related diseases and collagen loss-related disease.Type: ApplicationFiled: January 8, 2015Publication date: May 26, 2016Inventors: ERIC N. OLSON, EVA VAN ROOIJ